A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

This early-phase study is testing a new antibody-drug conjugate (ADC) called GSK5764227 that targets a protein called B7-H3, which is found on many brain tumor cells. It is being tested in people with recurrent grade 4 glioma (an aggressive brain tumor) or brain metastases (cancer that has spread to the brain from elsewhere in the body). **You may be eligible if...** - You are 18 or older - You have been diagnosed with glioblastoma (grade 4 brain tumor) that has returned after standard treatment including surgery and chemoradiation, OR you have brain metastases requiring surgical removal - You have tumor tissue available for analysis - Your cancer is measurable on brain imaging - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread to the lining around the brain and spinal cord (leptomeningeal disease) or is compressing the spinal cord - You cannot have an MRI scan with contrast - You have active serious infections, HIV, or active hepatitis B or C - You have had a recent heart attack, stroke, or severe heart failure - You have a history of serious lung disease or inflammation of the lungs - You have active autoimmune disease requiring systemic treatment in the past 2 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.